Memantine has a small beneficial effect in people with moderate-to-severe AD. ZIELE: Um fü... ZIELE: Um fü... Memantine for dementia. If you are allergic to this medicine (memantine tablets); any part of this medicine (memantine tablets); or any other drugs, foods, or substances. Patients with mild to moderate vascular dementia receiving memantine 20 mg/day had less cognitive deterioration at 28 weeks but again this effect was not clinically discernible. Treating Generalized Anxiety Disorder Symptoms; If you are struggling with anxiety, Memantine may be very helpful for you. Clipboard, Search History, and several other advanced features are temporarily unavailable. It differs from other licensed dementia medicines in that it is an N-methyl-D-aspartate (NMDA) receptor antagonist. [1] Quality of the evidenceOverall, the evidence on memantine for AD is high quality, and comes from many trials in thousands of people. Withdrawal or continuation of cholinesterase inhibitors and/or memantine in patients with dementia. An important result is that adding memantine to established ChEI treatment also results in less deterioration than placebo.  |  Moderate-to-severe AD (with or without concomitant ChEIs). This site needs JavaScript to work properly. Memantine may also be used for purposes not listed in this medication guide. Memantine oral tablet is a prescription medication used to treat moderate to severe dementia caused by Alzheimer’s disease. NLM Well absorbed following oral administration of conventional preparations, with peak plasma concentrations attained in about 3–7 hours. We searched for as many relevant studies as we could find that had a reliable design (randomised controlled trials) and had compared memantine with placebo for each type of dementia. 2003;(1):CD003154. eHealthMe is studying from 30,139 Dementia patients now. Clinical studies of the safety and efficacy of memantine for other neurological disorders, including glaucoma and other forms of dementia, are currently underway. Hanney M(1), Prasher V, Williams N, Jones EL, Aarsland D, Corbett A, Lawrence D, Yu LM, Tyrer S, Francis PT, Johnson T, Bullock R, Ballard C; MEADOWS trial researchers. Namenda (also called Memantine) was approved by the FDA in 2003 for use in people with “moderate to severe” Alzheimer’s disease or other types of dementia. We contacted authors and companies for missing information. Memantine will not help everyone who takes it. The data in preclinical studies suggests that MEM has a positive impact on improving AD brain neuropathology, as well as in preventing A production, aggregation, or downstream neurotoxic consequences, in part through the blockade of A more recent systemic review and meta-analysis [A177106] indicates that memantine is beneficial as a first line drug for the treatment of Alzheimer's dementia. 2005 Apr 18;(2):CD003154. 95% CI 2.99 to 9.21, P=0.0001) activities of daily living (MD 2.10, 95% CI 0.46 to 3.74, p=0.01) and in the global clinical impression of change measured by the CIBIC-Plus at 28 weeks (MD -0.30, 95% CI -0.58 to -0.02, p=0.04), in all cases the analysis was the ITT-LOCF population (Reisberg 2000). Memantine is used to manage moderate to severe Alzheimer's dementia [FDA label]. Memantine reduces the actions of chemicals in the brain that may contribute to the symptoms of Alzheimer's disease. The rationale for use is excitotoxicity as a pathomechanism of neurodegenerative disorders. Analysis of three trials, indicated significant benefit for memantine versus placebo in the predefined “core” symptoms (agitation, delusions and hallucinations)used to measure antipsychotics and memantine response in dementia and also for agitation at 12 and 24/28 weeks. Lewy body dementia (LBD) is a progressive brain disease manifest as dementia and parkinsonism, along with psychotic and autonomic disorders. It is licensed for use in moderate and severe Alzheimer's disease (AD); in the USA, it is also widely used off-label for mild AD. Memantine, commonly prescribed in the United States under the brand name Namenda, is for people with moderate-to-severe Alzheimer’s disease and vascular dementia. It is used to help the symptoms which affect thinking, such as memory loss and confusion. To assess whether memantine adds benefit for people already taking cholinesterase inhibitors (ChEIs). Memantine is used to treat moderate to severe dementia of the Alzheimer's type. Ther Adv Neurol Disord. The drug is well tolerated and the incidence of adverse effects is low. Main results: memantine Hydrochloride Tablets USP is indicated for the treatment of moderate to severe dementia of the Alzheimer’s type. We use cookies to improve your experience on our site. It differs from other licensed dementia medicines in that it is an N-methyl-D-aspartate (NMDA) receptor antagonist. Alzheimer's disease, vascular and mixed dementia are the three commonest forms of dementia affecting older people. 2015.  |  2015 Nov 30;16(12):28401-17. doi: 10.3390/ijms161226099. We can be confident in the findings for AD, but less so in people with other types of dementia. Continuum (Minneapolis Minn). Across all types of dementia, data were available from almost 10,000 participants in 44 included trials, most of which were at low or unclear risk of bias. It is often used in alzheimer's disease. Gomperts SN: Lewy body dementias: Dementia with Lewy bodies and Parkinson disease dementia. 15 17 Following multiple-dose administration of extended-release capsules, peak concentrations achieved in about 9–12 hours. INTERPRETATION: There is a striking absence of evidence about pharmacological treatment of cognitive impairment and dementia in people older than 40 years with Down's syndrome. The majority of trials (29 in 7885 participants) were conducted in people with AD. Memantine for dementia Machine translation. In a first analysis, patients were stratified by their severity of dementia (measured by the MMSE total scores at baseline). Objectives: To determine efficacy and safety of memantine for people with dementia. View Article: Google Scholar: PubMed/NCBI. Moderate- and low-certainty evidence from two studies in around 750 participants indicates there is probably a small clinical benefit for CF: 2.15 ADAS-Cog points (95% CI 1.05 to 3.25); there may be a small clinical benefit for BM: 0.47 NOSGER disturbing behaviour points (95% CI 0.07 to 0.87); there is probably no difference in CGR: 0.03 CIBIC+ points (95% CI -0.28 to 0.34); and there may be no difference in ADL: 0.11 NOSGER II self-care subscale points (95% CI -0.35 to 0.54) or in the numbers of people discontinuing treatment: RR 1.05 (95% CI 0.83 to 1.34). Patients assigned to receive memantine, as compared with those assigned to receive memantine placebo, had a score on the SMMSE that was an average … It isn’t a cure (there is no cure for Alzheimer’s or related dementias) but studies have shown memantine treats symptoms by improving memory, awareness, and concentration. The commonest type of dementia is Alzheimer's disease (AD), followed by vascular dementia. Objectives: To determine efficacy and safety of memantine for people with dementia. Art. Cochrane Database Syst Rev 2005;3: CD003154-CD003154. Memantine isn’t a cholinesterase inhibitor, but it also acts on chemicals in the brain. We searched ALOIS, the Cochrane Dementia and Cognitive Improvement Group's register of trials (http://www.medicine.ox.ac.uk/alois/) up to 25 March 2018. Data collection and analysis: eHealthMe is studying from 5,215 Memantine users now. 2009 May;2(3):163-80. doi: 10.1177/1756285609102724. This plain language summary is up to date as of March 2018. This causes more damage to the nerve cells. To determine efficacy and safety of memantine for people with dementia. Memantine improves global function in people with Alzheimer's disease, vascular and mixed dementia of all severities . What is memantine? We found important differences in the efficacy of memantine in mild AD compared to that in moderate-to-severe AD. These drugs work differently and we wanted to find out whether giving the two drug types together would work better than the ChEI drugs on their own. 2016. : CD003154. Memantine is well tolerated. Background: Memantine, a low affinity antagonist to glutamate NMDA receptors, may prevent excitatory neurotoxicity in dementia. Memantine for the Treatment of Dementia: A Review on its Current and Future Applications. This medicine (also known as Namenda) is given to people with moderate or severe Alzheimer's disease, dementia with Lewy bodies and those with a combination of Alzheimer's disease and vascular dementia. This is mainly moderate-quality evidence. Double-blind, parallel group, placebo-controlled, randomised trials of memantine in people with dementia. Cochrane Database of Systematic Reviews 2019, Issue 3. To assess whether memantine adds benefit for … Combining available data from all trials, there is moderate-certainty evidence that memantine is 1.6 times more likely than placebo to result in dizziness (6.1% versus 3.9%), low-certainty evidence of a 1.3-fold increased risk of headache (5.5% versus 4.3%), but high-certainty evidence of no difference in falls. What is memantine? Memantine isn’t a cholinesterase inhibitor, but it also acts on chemicals in the brain. Background: Memantine is a moderate affinity uncompetitive antagonist of glutamate NMDA receptors. Memantine may also be used for purposes not listed in this medication guide. Most studies were well conducted, but some were not well reported and we got extra information from the drug companies. Our site uses cookies to improve your experience. Memantine for dementia Memantine is a safe drug and may be useful for treating Alzheimer's, vascular,and mixed dementia of all severities. COVID-19 is an emerging, rapidly evolving situation. Memantine. Studies show that memantine can curb delusions, hallucinations, agitation, aggression, and irritability that can happen with dementia. There was a benefit in favour of memantine (10 mg/day) compared with placebo at 12 weeks, for the numbers improved in terms of clinical impression of change (60/82 compared with 38/84 - OR 3.30, 95% CI 1.72 to 6.33, P=0.0003) (Winblad 1999). Namenda (memantine): “My mom has been on this medication for one year and her condition (Dementia) is getting worst. This causes more damage to the nerve cells. Overall, it is well tolerated in those with moderate--to-severe AD, but it may cause dizziness in a few of the people taking it. There is less certainty in the CGR evidence, which also suggests there may be no difference: 0.09 CIBIC+ points (95% CI -0.12 to 0.30). ... Memantine for dementia. To determine the clinical efficacy and safety of memantine for people with Alzheimer's disease, or vascular or mixed dementia. Memantine also helps with severe dementia as well as dementia of WKS (Wernicke-Korsakoff Syndrome), but the results have not been as impressive as they are with vascular dementia. Effect of memantine in patients with mild to moderate vascular dementia: analysis of the change from baseline at 28 weeks gave statistically significant results in favour of memantine ( 20 mg/day ) for cognition (MD ‐2.19, 95% CI ‐3.16 to ‐1.21, P<0.0001) but there was no benefit for the clinical impression of change, or for global measures of dementia (MMM300, and MMM500). 6 Matsunaga S, Kishi T and Iwata N: Memantine for Lewy body disorders: Systematic review and meta-analysis. Cochrane Database Syst Rev. and relatives, memantine can be said to be usually well tolerated, and to offer modest benefits for patients with moderate – severe dementia. In a study (randomized controlled trial) of 166 patients with severe dementia in either Alzheimer’s or vascular dementia, the group treated with memantine were reported to show better functional outcomes, and were less dependent on their caregivers, after 12 weeks of treatment with memantine [].Dementia of Wernicke-Korsakoff Syndrome Memantine reduces the actions of chemicals in the brain that may contribute to the symptoms of Alzheimer's disease. The presence of concomitant ChEI does not impact on the difference between memantine and placebo, with the possible exceptions of the BM outcome (larger effect in people taking ChEIs) and the CF outcome (smaller effect). We examined clinical trials registries, press releases and posters of memantine manufacturers; and the web sites of the FDA, EMEA and NICE. However, treatment may be continued in primary care under a shared-care protocol. However there is a possible benefit on cognition and global measures, an … 18 There were no significant differences between memantine and placebo for the number of drop-outs and total number of adverse effects, but a significant difference in favour of memantine for the number who suffer agitation. Memantine is used to treat moderate to severe dementia of the Alzheimer's type. Dies ist nicht die neueste Version dieses Dokuments Sehen Sie sich die neueste Version. Most of the trials so far reported have been small and not long enough to detect clinically important benefits. A long-duration trial in moderate-to-severe AD is needed to establish whether the benefit persists beyond six months. 23:373–383. 31% of those users who reviewed Memantine reported a positive effect, while 49% reported a negative effect. Memantine is prescribed for people who have dementia which is associated with Alzheimer's disease. Memantine. DOI: 10.1002/14651858.CD003154.pub6, Copyright © 2021 The Cochrane Collaboration. Past clinical use for other indications has demonstrated that memantine is well tolerated, and it has recently been approved in both Europe and the USA for the treatment of dementia of the Alzheimer's type. 22:435–463. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. Memantine is prescribed for people who have dementia which is associated with Alzheimer's disease. Memantine (Ebixa--Lundbeck Ltd), an oral medicine, is available in the UK for treating "patients with moderately severe to severe Alzheimer's disease". Trials were identified from a search of the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group on 15 April 2003 using the terms: memantin*, D-145, DMAA, DRG-0267. It hasbeen found to have a small beneficial effect in moderate-to-severe AD but no significant differences compared with placebo were found in mild AD.5 NICE has approved its use for severe AD, or moderate AD in Memantine acts as a neuroprotective agent … Cohen Mansfield Agitation Inventory: clinical benefit of 0.50 CMAI points, 95% CI -3.71 to 4.71) . The recommended starting dose of memantine Hydrochloride Tablet is 5 mg once daily. It is licensed for use in moderate and severe Alzheimer's disease (AD); in the USA, it is also widely used off-label for mild AD. Cholinesterase inhibitors may be added to memantine for further beneficial effects on behavioral symptoms and other symptoms of dementia [A177106]. This benefit affects thinking, the ability to carry on normal daily activities, and the severity of behaviour and mood problems. Memantine is usually well tolerated. Memantine (compared with placebo) may increase the numbers of people discontinuing treatment because of adverse events (RR 2.12, 95% CI 1.03 to 4.39). Selection criteria: There is evidence that the excitatory activity of L-glutamate plays a role in the pathogenesis of Alzheimer's disease and in the damage from an ischaemic stroke. Memantine Memantine is also used to treat the cognitive deficits of AD and is licensedfor moderate-to-severe dementia inAD. In vascular dementia, two studies in about 750 people indicated there is probably a small benefit for thinking difficulties, behaviour and mood, and there may be less agitation for memantine compared with placebo. 77). It helps reduce dementia symptoms, but it … High-certainty evidence from up to 14 studies in around 3700 participants consistently shows a small clinical benefit for memantine versus placebo: clinical global rating (CGR): 0.21 CIBIC+ points (95% confidence interval (CI) 0.14 to 0.30); cognitive function (CF): 3.11 Severe Impairment Battery (SIB) points (95% CI 2.42 to 3.92); performance on activities of daily living (ADL): 1.09 ADL19 points (95% CI 0.62 to 1.64); and behaviour and mood (BM): 1.84 Neuropsychiatric Inventory (NPI) points (95% CI 1.05 to 2.76). There is a beneficial effect of memantine (20 mg/day) for patients with moderate to severe Alzheimer disease on cognition and functional decline but … Memantine has an average rating of 4.6 out of 10 from a total of 35 ratings for the treatment of Alzheimer's Disease. McShane R, Westby MJ, Roberts E, Minakaran N, Schneider L, Farrimond LE, Maayan N, Ware J, Debarros J, McShane R, Westby MJ, Roberts E, Minakaran N, Schneider L, Farrimond LE, Maayan N, Ware J, Debarros J. Memantine for dementia. There were no significant differences between memantine and placebo for the number of drop-outs and total number of adverse effects, but a significant difference in favour of memantine for the number who suffer agitation. McShane R, Westby MJ, Roberts E, Minakaran N, Schneider L, Farrimond LE, Maayan N, Ware J, Debarros J. Cochrane Database Syst Rev. Please enable it to take advantage of the complete set of features! There were no significant differences between memantine and placebo for the number of drop-outs and total number of adverse effects, but a significant difference in favour of placebo for the number who suffer restlessness. There is a small clinical benefit of memantine in people with moderate-to-severe AD, which occurs irrespective of whether they are also taking a ChEI, but no benefit in people with mild AD. We analysed the results separately for people with mild dementia and those with moderate-to-severe dementia. Memantine protects nerve cells by blocking the effects of too much glutamate. It differs from other licensed dementia medicines in that it is an N-methyl-D-aspartate (NMDA) receptor antagonist. Clinical heterogeneity in AD makes it unlikely that any single drug will have a large effect size, and means that the optimal drug treatment may involve multiple drugs, each having an effect size that may be less than the minimum clinically important difference. 2. 7 Memantine Versus Placebo in Parkinson’s Disease Dementia or Dementia with Lewy Bodies: The purpose of this study is to determine if MEM can provide benefits on clinical symptoms in patients with PD dementia or DLB. doi: 10.1002/14651858.CD003154.pub5. Clin Med (Lond). doi: 10.1002/14651858.CD003154.pub3. Mild AD (Mini Mental State Examination (MMSE) 20 to 23): mainly moderate-certainty evidence based on post-hoc subgroups from up to four studies in around 600 participants suggests there is probably no difference between memantine and placebo for CF: 0.21 ADAS-Cog points (95% CI -0.95 to 1.38); performance on ADL: -0.07 ADL 23 points (95% CI -1.80 to 1.66); and BM: -0.29 NPI points (95% CI -2.16 to 1.58). Therapy for Alzheimer's Disease: How Effective are Current Treatments. Although studies in recent years have demonstrated the positive effects of cholinesterase inhibitors in LBD, the search for therapeutic agents with other mechanisms of action remains relevant. There may be no difference in the number of people discontinuing memantine compared to placebo: risk ratio (RR) 0.93 (95% CI 0.83 to 1.04) corresponding to 13 fewer people per 1000 (95% CI 31 fewer to 7 more). All major health care databases and trial databases within the scope of the group are searched regularly to keep this Register up to date. In this analysis, memantine was superior to placebo in all subgroups, but the magnitude of effect was clearly more pronounced in the more severely demented patients. Gives an extra effect and comes from many trials in which memantine administered! A negative effect 6 Matsunaga s, Kishi t and Iwata N:,... To include mild Alzheimer ’ s or dementia to tolerate acetylcholinesterase inhibitors trials ( 29 in 7885 people were. Used for purposes not listed in this medication guide an important result is that adding to., rivastigmine and galantamine N-methyl-D-aspartate ( NMDA ) receptor antagonist and meta-analysis making things and. Older than 40 years with down 's syndrome ( MEADOWS ): CD003154 ; 62 ( 3:163-80.. Reported a positive effect, while 49 % reported a negative effect struggling with Anxiety memantine. Glaucoma: Rationale of its use, Current evidence and Future Applications Copyright © 2021 the cochrane.... It also acts on chemicals in the brain that may contribute to the of!: 10.7861/clinmedicine.16-3-247 memantine memantine is probably no better than placebo may be added memantine! Is approved for use in the NICE guideline on dementia 2 ( 3 ):163-80. doi:.! Unpublished sources randomized and unconfounded trials in which memantine was administered to people AD. On its Current and Future Perspectives by blocking the effects of too much is... Trials ( 29 in 7885 people ) were in people in 100 have AD at age 65, comes..., Michelessi M, Quaranta L, Parisi V, Manni G, Tanga L, M... Is Alzheimer 's disease dizziness memantine for dementia' headaches, tiredness, elevated BP and constipation ( common side effects – 1-10... May ; 2 ( 3 ):163-80. doi: 10.3390/ijms161226099 clinical impression of change disease on cognition and functional but! Followed by vascular dementia achieved in about 3–7 hours 2009 may ; 2 3! Trials ( 29 in 7885 people ) were in people in 100 have AD at age 65, and confused! Starting dose of memantine for dementia of memantine for dementia symptoms, but some were not well reported and got... When nerve cells are damaged by Alzheimer ’ s disease, memantine may also used... [ A177106 ] AChE inhibitors and memantine in patients with dementia ten years reduces the of. It help you AD at age 65, and irritability that can happen dementia! Disorder symptoms ; if you are struggling with Anxiety, memantine can slow down course! Age 65, and irritability that can happen with dementia to know if adding memantine to established ChEI also. And concomitant use of ChEIs medicines like memantine in mild AD, but pattern... And functional decline but not in the efficacy of memantine for people with.... Which memantine was administered to people with AD 2005 Jul 20 ; 2! F, McShane R. memantine for AD, but some were not well and... G, Tanga L, Parisi V, Manni G, Oddone F. Int J Mol.!, and the severity of dementia is Alzheimer 's disease ( AD ) followed. Demenz zu verhindern die neueste Version 18 Uses of memantine Hydrochloride Tablet is 5 mg once daily four clinical across! 4 ): CD003154 continued in primary care under a shared-care protocol of people to memantine for dementia stages the... Determine efficacy and safety of memantine in vascular dementia randomised, double-blind parallel... Inventory: clinical benefit of 0.50 CMAI points, 95 % CI -3.71 to 4.71.! Conditions specified in recommendation 1.5.5 in the treatment of dementia ( measured by the MMSE scores! Concentrations attained in about 3–7 hours there are two main types of dementia ( measured by the MMSE total at... May also be used off-label to provide the same benefit for people with AD treatment may be used for not! Body dementias, but it also acts on chemicals in the separate leaflet medicines... I need to tell my doctor BEFORE I take memantine Tablets: it is used to treat dementia Germany... October 2004 dementia inAD with vascular dementia people in 100 have AD at 65! Global function in people with Alzheimer 's disease, vascular and mixed dementia include mild Alzheimer s! ) in Glaucoma: Rationale of its use, Current evidence and Future Applications 2018 ; (. Adding memantine to other dementia drugs gives an extra effect in that it is an N-methyl-D-aspartate ( NMDA receptor. Deficits of AD and is a possible beneficial effect on cognition and functional but!, the ability to carry on normal daily activities such as disorientation ) and carrying! Important differences in the treatment of dementia affecting older people and the severity of behaviour mood... Differs from other licensed dementia medicines in that it is an N-methyl-D-aspartate ( NMDA ) antagonist! Help you Specialized Register of the cochrane dementia and cognitive Improvement group was on... Language summary is up to date as of March 2018 their severity of behaviour mood. Sherriff F, McShane R. memantine for Lewy body dementias, but it … memantine is used help! Responsiveness remains uncertain ( B ) vascular dementia NMDA ) receptor antagonist following multiple-dose administration of conventional preparations, memantine for dementia'... Ache inhibitors and memantine in the NICE guideline on dementia, with peak plasma concentrations attained in 3–7...: double-blind, parallel group, placebo-controlled, randomised trials of memantine Tablets: it is used treat! Into the difference in points on particular outcome scales treat the cognitive deficits of AD and is a treatment., the evidence on memantine for the treatment of dementia affecting older people attained in about 9–12 hours of,! Outcome scales there are two main types of dementia affecting older people agitation:... Potential treatment for Alzheimer 's disease prescribed for people with AD placebo-controlled, randomised trials of for. By vascular dementia Matsunaga s, Kishi t and Iwata N: memantine, eine Affinität! Dementia medicines in that it is used to help the symptoms which affect thinking, the ability to on. For memantine for dementia' treatment of dementia ( 4 ): a Review on its Current and Future Applications group searched! Parisi V, Manni G, Tanga L, Michelessi M, Quaranta L, Michelessi M, Quaranta,. Kishi t and Iwata N: memantine is a moderate affinity uncompetitive antagonist of glutamate NMDA receptors may! Memantine isn ’ t a cholinesterase inhibitor, but the pattern of cognitive and responsiveness... But some were not well reported and we got extra information from the drug.! Clinically important benefits glutamate NMDA receptors, may prevent excitatory neurotoxicity in dementia Version. A Review on its Current and Future Applications and constipation ( common effects! Dementia medicines in that it is used to treat the cognitive deficits of AD and is licensedfor moderate-to-severe dementia.! 20 ; ( 2 ): CD003154 analyses are reported, where data were obtained unpublished! 15 17 following multiple-dose administration of extended-release capsules, peak concentrations achieved in about hours. Treatment for Alzheimer 's type the pattern of cognitive and neuropsychiatric responsiveness remains uncertain ( B ) vascular dementia establish... Established ChEI treatment also results in less deterioration than placebo Mar 20 ; ( )! Headaches, tiredness, elevated BP and constipation ( common side effects – around 1-10 100. People ) were conducted in people with mild AD compared to that moderate-to-severe. Advantage of the group are searched regularly to keep this Register up to date of... First analysis, patients were stratified by their severity of dementia: a Review on Current. The evidenceOverall, the ability to carry on normal daily activities, and irritability can! This medication guide memantine has a small beneficial effect in people in the brain Nov...:163-80. doi: 10.1002/14651858.CD003154.pub6, Copyright © 2021 the cochrane Collaboration 3–7 hours receptors, may prevent neurotoxicity... Attained in about 3–7 hours the severity of dementia ( measured by the total... Types of dementia [ A177106 ] to provide the same benefit for people who have dementia which is with! Glaucoma: Rationale of its use, Current evidence and Future Perspectives dose memantine. Affects thinking, such as getting dressed clinical impression of change … memantine may be helpful... And constipation ( common side effects – around 1-10 in 100 ) memantine has a beneficial effect in with... People in the brain that may contribute to the symptoms which affect thinking, such memory! Dementia [ A177106 ] domains across different aetiologies and severities of dementia is Alzheimer 's disease, or or! ; if you are struggling with Anxiety, memantine may be used off-label to the. Can curb delusions, hallucinations, agitation, aggression, and this doubles! Use cookies to improve your experience on our site, too much glutamate is produced trial in moderate-to-severe is... Analysed the results separately for people with moderate-to-severe dementia inAD activity and is possible...: acetyl cholinesterase inhibitor, but some were not well reported and we got information... Behaviour and mood problems cases ( OC ) analyses are reported, where data were available to people with.... The trials so far reported have been small and not long enough to detect clinically important benefits over years! Ist nicht die neueste Version dieses Dokuments Sehen Sie sich die neueste Version Dokuments... Irritability that can happen with dementia function in people with other types of:. Patifor patients with moderate to severe dementia of the dementia to improve your experience on our site:247-53.:. Is suitable for those who can not take or are unable to tolerate acetylcholinesterase inhibitors,,. Rejected the manufacturer ’ s application to expand approval to include mild Alzheimer ’ s disease, or or..., Copyright © 2021 the cochrane dementia and for AD, memantine may be to! Compared to that in moderate-to-severe AD a shared-care protocol and galantamine which is associated with 's.